Certolizumab pegol (Certolizumab) 是重组、聚乙二醇化、抗原结合片段的人源化单克隆抗体，可选择性靶向和中和肿瘤坏死因子-α (TNF-α)。 Certolizumab pegol 可用于类风湿关节炎和克罗恩病的研究。

Certolizumab pegol (Certolizumab) is a recombinant, polyethylene glycolylated, antigen-binding fragment of a humanized monoclonal antibody that selectively targets and neutralizes tumour necrosis factor-α (TNF-α). Certolizumab pegol can be used for rheumatoid arthritis and Crohn disease research.

Liquid

Certolizumab pegol (Certolizumab) neutralizes soluble TNFα with an IC90 of 3 ng/mL.
Certolizumab pegol (0-100 μg/mL, 1 h) completely inhibits subsequent production of IL-1β in response to LPS at concentrations over 1μg/mL in human monocytes.
Certolizumab pegol does not mediate complement-dependent cytotoxicity (CDC) or antibody-dependent cell-mediated cytotoxicity (ADCC).
Certolizumab pegol does not induce apoptosis of activated human monocytes or peripheral blood lymphocytes (PBLs) or result in degranulation or loss of cell membrane integrity in polymorphonuclear cells. has not independently confirmed the accuracy of these methods. They are for reference only.

Certolizumab pegol (Certolizumab) (10 μg; i.p.; single dose) reduces the severity of acute pancreatitis. has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Healthy Wistar Albino male rat

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

[1]. Deeks ED. Certolizumab pegol: a review of its use in the management of rheumatoid arthritis. Drugs. 2013 Jan;73(1):75-97.
[2]. Nesbitt A, et al. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents. Inflamm Bowel Dis. 2007 Nov;13(11):1323-32.